RECRUITING

eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.

Official Title

A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

Quick Facts

Study Start:2022-09-28
Study Completion:2026-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05427240

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age or older
  2. * Speak and understand English
  3. * Male or Female
  4. * No prior germline genetic testing
  5. * Meet current National Comprehensive Cancer Network (NCCN) guidelines for germline genetic testing
  1. * Uncorrected or uncompensated hearing and/or vision impairment
  2. * Uncorrected or uncompensated speech defects
  3. * Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Contacts and Locations

Study Contact

Angela R Bradbury, MD
CONTACT
215 615 3341
Angela.Bradbury@pennmedicine.upenn.edu
Dominique Fetzer, BA
CONTACT
215 662 2753
Dominique.Fetzer@pennmedicine.upenn.edu

Principal Investigator

Angela R Bradbury, MD
PRINCIPAL_INVESTIGATOR
University of Pennsylvania

Study Locations (Sites)

Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Angela R Bradbury, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-28
Study Completion Date2026-01

Study Record Updates

Study Start Date2022-09-28
Study Completion Date2026-01

Terms related to this study

Additional Relevant MeSH Terms

  • Cancer